Results 121 to 130 of about 59,389 (246)
Computational and Systems Oncology, Volume 6, Issue 1, December 2026.ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman +2 more
wiley +1 more source
Extramedullary Disease—Achilles Heel in Myeloma?
American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar +7 more
wiley +1 more source
Cell Toxicity and Autophagy in A549 Cells Treated With Surface‐Functionalized Graphene Derivatives
Journal of Applied Toxicology, Volume 46, Issue 3, Page 821-832, March 2026.ABSTRACT Graphene oxide and its derivatives have unique physical and chemical properties with applications in many different fields. However, their biological effects and mechanisms of intracellular toxicity have not been completely clarified. In this study, we investigated the cytotoxic and autophagic activities of graphene oxide and its derivatives ...
Tae Yun Park +6 more
wiley +1 more source
Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors
AbstractPhosphodiesterase 3A (PDE3A) modulators are emerging anticancer agents for tumors that co-express PDE3A and Schlafen 12 (SLFN12), promoting the formation of a cytotoxic PDE3A-SLFN12 complex. The effect correlates with PDE3A and SLFN12 expression levels.
Kirsi Toivanen +14 more
openaire +1 more source
Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery
MedComm – Oncology, Volume 5, Issue 1, March 2026.This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem +9 more
wiley +1 more source
MedComm – Oncology, Volume 5, Issue 1, March 2026.Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang +7 more
wiley +1 more source
Covalent Peptide‐Based N‐Myc/Aurora‐A Inhibitors Bearing Sulfonyl Fluoride Warheads
Journal of Peptide Science, Volume 32, Issue 3, March 2026.N‐Myc‐derived peptidomimetics bearing aryl sulfonyl fluoride warheads were shown to act as effective N‐Myc/Aurora‐A PPI inhibitors, selectively labelling Aurora‐A in a recognition‐directed manner. ABSTRACT Orthosteric inhibition of the N‐Myc/Aurora‐A protein–protein interaction (PPI) represents a potential mechanism by which degradation of N‐Myc can be
Robert S. Dawber +6 more
wiley +1 more source
The role of cytokines in ovarian cancer drug resistance
International Journal of Cancer, Volume 158, Issue 4, Page 821-834, 15 February 2026.Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang +7 more
wiley +1 more source